About Us
Company Leadership
Board of Directors
Investors and Partners
Pipeline
Cefepime-Taniborbactam
Ceftibuten/VNRX-7145
VNRX-9945
PBP Inhibitor
Expanded Access
Publications
Manuscripts
Posters
News & Events
Press Releases
In the News
Events
Careers
Contact
Publications
Publications
Manuscripts
Posters
Cefepime/Taniborbactam
Ceftibuten/VNRX-7145
News
Reasons to be optimistic about new antibiotic development
November 11, 2020
The Pasteur Act - A View from Industry
October 26, 2020
> See all News
Posters
Rescue of Ceftibuten Activity by the Oral β-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D β-Lactamases
Evaluation of the in vitro activity of cefepime plus VNRX-5133 and comparative agents against carbapenem-resistant Enterobacteriaceae.
> See all Posters
Manuscripts
Click here for Access to the Journal Article
Click here for Access to the Journal Article
> See all Manuscripts
Manuscripts
Click here for Access to the Journal Article
Click here for Access to the Journal Article
>> More Manuscripts
Posters
Rescue of Ceftibuten Activity by the Oral β-Lactamase Inhibitor VNRX-7145 against Enterobacteriaceae Expressing Class A, C and/or D β-Lactamases
Evaluation of the in vitro activity of cefepime plus VNRX-5133 and comparative agents against carbapenem-resistant Enterobacteriaceae.
Oral ceftibuten/VNRX-7145 shows equivalent activity in vitro to IV therapeutics against MDR Enterobacteriaceae.
Cefepime/VNRX-5133 Broad-Spectrum Activity is Maintained against Emerging KPC- and PDC-Variants in Multidrug Resistant K. pneumoniae and P. aeruginosa.
>> More Posters
You are using a browser that is not supported. Please consider changing your browser
